AI Article Synopsis
- The TACT study evaluated the long-term effects of EDTA chelation therapy on patients with stable coronary disease, finding that it reduced the risk of major cardiovascular events.
- Quality of life measures, including the Duke Activity Status Index and Mental Health Inventory, showed no significant differences between the chelation and placebo groups over a 2-year period.
- Overall, the study concluded that EDTA chelation therapy did not improve quality of life in patients post-myocardial infarction despite its benefits in reducing certain health risks.
Article Abstract
Background: The National Institutes of Health.funded Trial to Assess Chelation Therapy (TACT) randomized 1708 stablecoronary disease patients aged .50 years who were .6 months post.myocardial infarction (2003.2010) to 40 infusions ofa multicomponent EDTA chelation solution or placebo. Chelation reduced the primary composite end point of mortality,recurrent myocardial infarction, stroke, coronary revascularization, or hospitalization for angina (hazard ratio, 0.82; 95%confidence interval, 0.69.0.99; P=0.035).
Methods And Results: In a randomly selected subset of 911 patients, we prospectively collected a battery of quality-of-life(QOL) instruments at baseline and at 6, 12, and 24 months after randomization. The prespecified primary QOL measures were the Duke Activity Status Index (Table I in the Data Supplement) and the Medical Outcomes Study Short-Form 36 Mental Health Inventory-5. All comparisons were by intention to treat. Baseline clinical and QOL variables were well balanced in the 451 patients randomized to chelation and in the 460 patients randomized to placebo. The Duke Activity Status Index improved in both groups during the first 6 months of therapy, but we found no evidence for a treatment-related difference (mean difference [chelation.placebo] during follow-up, 0.9 [95% confidence interval, .0.7 to 2.6; P=0.27]).There was no statistically significant evidence of a treatment-related difference in the Mental Health Inventory-5 during follow-up (mean difference, 1.0; 95% confidence interval, .0.1 to 2.0; P=0.08). None of the secondary QOL measures showed a consistent treatment-related difference.
Conclusions: In stable, predominantly asymptomatic coronary disease patients with a history of myocardial infarction,EDTA chelation therapy did not have a detectable effect on QOL during 2 years of follow-up.
Clinical Trial Registration: URL: http://clinicaltrials.gov. Unique identifier: NCT00044213.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146707 | PMC |
| http://dx.doi.org/10.1161/CIRCOUTCOMES.114.000977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of potent anti-toxoplasmosis drugs from secondary metabolites in Citrus limon (lemon) leaves, supported in-silico study.
Sci Rep
January 2025
Department of Zoonotic Diseases, National Research Centre, Dokki, Giza, 12622, Egypt.
Toxoplasmosis induced by Toxoplasma gondii is a well-known health threat, that prompts fatal encephalitis increased with immunocompromised patients, in addition, it can cause chorioretinitis, microcephaly, stillbirth in the fetus and even led to death. Standard therapy uses sulfadiazine and pyrimethamine drugs revealed beneficial results during the acute stage, however, it has severe side effects. UPLC-ESI-MS/MS used to explore C.
View Article and Find Full Text PDFIron induces blood-brain barrier alteration contributing to cognitive impairment in β-thalassaemia mice.
Sci Rep
January 2025
Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Iron overload has been associated with cerebrovascular disease and cognitive impairment in β-thalassaemia patients, typically appearing earlier than in the general population. However, the mechanisms of iron overload on cerebrovascular pathology remain unclear. This study investigated the effects of heavy iron overload on the blood-brain barrier and neurohistology, particularly in the CA3 region of hippocampus and its contribution to cognitive impairment in β-thalassaemia mice.
View Article and Find Full Text PDFMultifunctional selenium-doped carbon dots for modulating Alzheimer's disease related toxic ions, inhibiting amyloid aggregation and scavenging reactive oxygen species.
Int J Biol Macromol
December 2024
Department of Chemistry, School of Chemistry and Chemical Engineering, Northwestern Polytechnical University, 127 Youyi Road, Xi'an 710072, China. Electronic address:
Article Synopsis
- β-Amyloid deposition, oxidative stress, and metal ion imbalance are key features of Alzheimer's disease, creating a need for effective multi-target therapies.
- Researchers developed multifunctional selenium-doped carbonized polymer dots (SeCDs) to inhibit Aβ aggregation, reduce reactive oxygen species (ROS), and chelate copper ions.
- SeCDs successfully clear harmful radicals and bind Cu ions, lowering cytotoxicity related to Aβ-Cu complexes, and show promise as a treatment option by reducing intracellular ROS levels.
Association of Serum Ferritin With Growth and Endocrine Function in Thalassemia Major Children in North India: An Observational Study.
Cureus
November 2024
Community Medicine, Baba Raghav Das Medical College, Gorakhpur, IND.
Article Synopsis
- Thalassemia, particularly beta-thalassemia major, is a hereditary anemia marked by insufficient beta-globin chain production, leading to iron overload from frequent blood transfusions, with significant health complications like endocrinopathies.
- The study focused on children aged 6 months to 14 years, examining growth and endocrine function in relation to serum ferritin levels, which indicate iron overload.
- Results revealed a high prevalence of endocrinopathy, with short stature being the most commonly observed issue, particularly among boys and younger children.
DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application.
JACS Au
December 2024
Department of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, United States.
Targeting iron metabolism has emerged as a novel therapeutic strategy for the treatment of cancer. As such, iron chelator drugs are repurposed or specifically designed as anticancer agents. Two important chelators, deferasirox (Def) and triapine (Trp), attack the intracellular supply of iron (Fe) and inhibit Fe-dependent pathways responsible for cellular proliferation and metastasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!